Trial Profile
A Randomized, Parallel Control, Exploratory Trial to Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in Subjects With Advanced or Metastatic of the Non-small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 03 Feb 2021 Status changed from recruiting to discontinued.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 24 Aug 2017 New trial record